ClinicalTrials.gg
Active, not recruitingNCT05407324DAZALSUpdated Sep 24, 2026

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

A Phase 2 interventional study of Dazucorilant 300 mg and Dazucorilant 150 mg in Amyotrophic Lateral Sclerosis, sponsored by Corcept Therapeutics. Active, not recruiting at 35 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies in Amyotrophic Lateral Sclerosis with a site in France — 28 open to participants now, 36 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · France.

Planned enrollment
26th of 103
279 · median 83
Started
2022
with 10 others
Phase 2
24 of 132
2 open now
Primary completion
2026-10
later than 11 of 35 live
Registered
96th of 132
by date

Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, this one is the 26th largest by planned enrollment of the 103 interventional ones that give a count, is one of 11 that started in 2022, is one of 24 in phase 2, reaches primary completion later than 11 of the 35 other live ones, and was the 96th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

28 of the 132 studies in Amyotrophic Lateral Sclerosis with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Amyotrophic Lateral Sclerosis with a site in France, or all of them as a file.
02

Study summary

The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

Read the detailed description

In Part 1, eligible ALS patients will be randomized to one of three treatment arms (1:1:1) across North America and Europe for a 24-week double-blind treatment period. Patients who complete participation (i.e., complete all visits) in the double-blind treatment period will be eligible for participation in a 132-week open-label extension (OLE) study. A daily dose of 300 mg dazucorilant will be used in the OLE period. Patients who complete the double-blind treatment period and who do not enter the OLE will enter the 132-week follow-up period.

In Part 2, eligible ALS patients will receive open-label treatment to evaluate dose titration and tolerability of dazucorilant. The dose titration will begin with an initial 75 mg once daily dose, and the dose will be titrated up as tolerated in 75 mg increments until the 300 mg once daily target dose is reached and maintained for 3 weeks. Patients who complete participation in the dose-titration treatment period will be eligible to continue treatment with dazucorilant 300 mg once daily in a 52-week open-label extension portion of the study.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS, Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients ≥18 years of age with sporadic or familial ALS. In Part 1, patients must have a risk of ALS progression characterized by a European Network for the Cure of ALS (ENCALS) risk profile score ≥ -6 and ≤ -3. In Part 2 patients must have a risk of ALS progression characterized by an Treatment Research Initiative to Cure ALS (TRICALS) risk profile score ≥ -7 and ≤ -3.
  • If taking riluzole, edaravone, and/or sodium phenylbutyrate and taurursodiol, must be on a stable dose prior to Screening. Sodium phenylbutyrate and taurursodiol are not permitted for patients enrolled in Part 2 of the study.
  • Part 2 only: Patients with a pathogenic mutation in superoxide dismutase 1 gene (SOD1) must not be receiving treatment with tofersen or eligible for treatment with tofersen if available. Patients who have received prior treatment with tofersen and discontinued due to safety and/or efficacy reasons prior to Screening are eligible.
  • Part 2 only: Use of ultra high-dose methylcobalamin for the treatment of ALS is permitted provided the patient has been on a stable dose for ≥11 weeks prior to the Day 1 visit.

Exclusion criteria

Exclusion Criteria:

  • History of a non-ALS neurologic disorder
  • Inability to swallow capsules.
  • Blood count \<150,000/mm\^3.
  • Renal impairment indicated by Estimated (eGFR) ≤30 mL/min/1.73 m\^2. Part 2 only: Patients with a recent history of acute kidney injury should have returned to their baseline renal function (i.e, eGFR prior to acute kidney injury) prior to enrollment.
  • (HIV) or current chronic/active infection with virus or virus. Part 2 only: Known history of HIV or chronic/active infection with hepatitis C or hepatitis B virus; testing does not need to be performed if infection status is unknown.
  • Women who are pregnant, planning to become pregnant, or are breastfeeding.
  • Use of non-invasive ventilation (NIV) or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation.
  • Cancer that is currently being treated (except adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin, stage I endometrial cancer or carcinoma in situ of the cervix or breast) or a history of cancer with an expected survival \< 2 years.
  • Current or anticipated need of a diaphragm pacing system (DPS).
  • Previous exposure or treatment with receptor modulators or antagonists.
  • Taking, or have taken, any systemic, inhaled, or potent dermatologic topical corticosteroids (Class I to III) within a period equivalent to 5 half-lives of the corticosteroid used prior to first dose of study drug. Patients who have stopped glucocorticoid use should have an alternative option if their condition deteriorates during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
279 participants (estimated)

Study arms

  • Experimental
    Part 1: CORT113176 (Dazucorilant) 300 mg

    300 mg of dazucorilant will be administered once daily.

    Drug: Dazucorilant 300 mg

  • Experimental
    Part 1: CORT113176 (Dazucorilant) 150 mg

    150 mg of dazucorilant will be administered once daily.

    Drug: Dazucorilant 150 mg · Other: Placebo

  • Placebo comparator
    Part 1: Placebo (matched to study drug)

    Placebo will be administered once daily.

    Other: Placebo

  • Experimental
    Part 2: CORT113176 (Dazucorilant) 75 - 300 mg Dose-titration

    75 mg of dazucorilant will be administered once daily for 1 week, and increased weekly in 75 mg increments up to 300 mg once daily.

    Drug: Dazucorilant

Interventions

  • 300 mg of dazucorilant will be administered once daily in 4 capsules of 75 mg dazucorilant/capsule.

    Also known as: CORT113176

  • Dazucorilant and placebo will be administered once daily in 4 capsules, 2 capsules with 75 mg dazucorilant/capsule, and 2 capsules of placebo equivalent.

    Also known as: CORT113176

  • OtherPlacebo

    Placebo will be administered once daily in capsules of placebo equivalent.

  • Dazucorilant will be administered once daily in 75-mg capsules.

    Also known as: CORT113176

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.

    This outcome measure is assessed in study Part 1.

    Time frame: Baseline to Week 24

  2. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs

    This outcome measure is assessed in study Part 1.

    Time frame: Baseline to Week 24

  3. Incidence of treatment-emergent AEs and SAEs

    This outcome measure is assessed in study Part 2.

    Time frame: Baseline up to Week 12

  4. Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drug

    This outcome measure is assessed in study Part 2.

    Time frame: Baseline up to Week 12

Secondary outcomes

  1. Change from Baseline to Week 24 in muscle strength (assessed using hand-held dynamometer)

    This outcome measure is assessed in study Part 1.

    Time frame: Baseline to Week 24

  2. Change from Baseline to Week 24 in Percent Slow Vital Capacity

    This outcome measure is assessed in study Part 1.

    Time frame: Baseline to Week 24

  3. Change from Baseline to Week 24 in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)

    This outcome measure is assessed in study Part 1.

    Time frame: Baseline to Week 24

  4. Time to Death

    This outcome measure is assessed in study Part 1.

    Time frame: From randomization date to the date of death from any cause up to 156 weeks

07

Study locations

35 sites
  • 062
    Phoenix, Arizona 85013, United States
  • 278
    San Francisco, California 94109, United States
  • 287
    Neptune City, New Jersey 07753, United States
  • 353
    New York, New York 10032, United States
  • 108
    Leuven, 3000, Belgium
  • 425
    Hamilton, Ontario L8N 3Z5, Canada
  • 273
    Montreal, Quebec H3A2B4, Canada
  • 422
    Bron, 69500, France
  • 258
    Lille, 59037, France
  • 257
    Limoges, 87042, France
  • 261
    Marseille, 13385, France
  • 423
    Montpellier, 42395, France
  • 259
    Nice, 06001, France
  • 262
    Paris, 75651, France
  • 256
    Tours, 37000, France
  • 255
    Berlin, 13353, Germany
  • 270
    Bonn, 53127, Germany
  • 268
    Dresden, 1307, Germany
  • 260
    Hanover, 30625, Germany
  • 265
    Jena, 7747, Germany
  • 386
    München, 81675, Germany
  • 267
    Rostock, 18147, Germany
  • 269
    Ulm, 89081, Germany
  • 253
    Dublin, D09 YD60, Ireland
  • 264
    Utrecht, 3584 CW, Netherlands
  • 283
    Bydgoszcz, 85-163, Poland
  • 385
    Krakow, 30721, Poland
  • 254
    Warsaw, 01-684, Poland
  • 274
    Warsaw, 02-473, Poland
  • 302
    Barcelona, 08003, Spain
  • 115
    Barcelona, 08035, Spain
  • 303
    Madrid, 28046, Spain
  • 282
    Málaga, 29010, Spain
  • 194
    Valencia, 46026, Spain
  • 263
    Stoke-on-Trent, ST4 6QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Oct 2026, 47 months after the start.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's planned 47 months is above that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2022
First posted
Jun 7, 2022
StartActual
Nov 15, 2022
Primary completionEst.
Oct 2026
CompletionEst.
Nov 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05407324
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Nov 15, 2022
Primary completion
Oct 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

Sophia Majeed, PharmD, PhD
study director · Corcept Therapeutics Incorporated

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT113176

Start the discussion